I am very excited to share details with you surrounding the significant achievement that was announced in a media release this morning. Our science team has successfully created a water solubilized selamectin product. To date, the selamectin drug was considered a virtually water insoluble molecule. This drug has tremendous potential in treating parasitic infestations in husbandry and companion animals, as well as mycobacterium-based infections including Buruli Ulcer, Leprosy and Tuberculosis.
Tuberculosis (TB) is a bacterial infection that can spread through the air and is a global disease found in every country in the world. According to the non-profit organization TB Alliance, Tuberculosis it is the leading infectious cause of death worldwide. The World Health Organization estimates that 1.8 billion people - close to one quarter of the world's population - are infected with Mycobacterium tuberculosis (M.tb), the bacteria that causes TB. In 2020, 10 million fell ill from TB and 1.4 million died – a rate of death of 3,836 people per day. The global economic cost of TB is estimated to reach over 16 trillion dollars by the year 2050*.
Apply our Quicksol™ solubilization technology, MVMD scientists were successful in solubilizing selamectin at 15mg/ml into a water solution without any organic solvents, a critical achievement to allow formulation into topical application creams, oral rapid dissolve sublingual tablets, and injectable applications.
These photos below were taken from my personal iPhone last evening in our formulation lab and will help you better understand just how amazing this work is. I have said before that solubility is one of the most important requirements to achieve desired concentration in systemic circulation to optimize a drug’s effectiveness.
Selamectin in water versus Mountain Valley MD's Quicksol™ Technology
If you recall, MVMD previously filed a patent application to cover all highly solubilized macrocyclic lactones, including ivermectin and selamectin. Having now successfully applied the Quicksol™ solubilization technique to the selamectin drug, MVMD will proceed to formulate a new product, Selactosol™ 1.5%, for preclinical evaluation trials of mycobacterium-based infections such as Buruli Ulcer, Leprosy and Tuberculosis.
You can read the full media release on our website:
This is an incredible step forward and another powerful tool in our arsenal to tackle the most significant human and husbandry animal health problems facing our global population. Our team is moving fast and remain relentlessly focused on freeing the world from the scourge of disease. Thank you for your ongoing support of our mission! We are just getting started!
President & CEO, Mountain Valley MD